Gina B. Scott

Beckett Street
Leeds, ENG LS97TF, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.

Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.

Journal: Molecular therapy oncolytics
Published: October 19, 2022

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.

Journal: Journal for immunotherapy of cancer
Published: February 17, 2021

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Journal: Journal for immunotherapy of cancer
Published: February 13, 2019

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 04, 2018

Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.

Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.

Journal: Cellular immunology
Published: April 01, 2015

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Journal: Leukemia
Published: December 16, 2014

Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.

Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.

Journal: Clinical and experimental immunology
Published: November 18, 2014

Epithelial cell ADAM17 activation by Helicobacter pylori: role of ADAM17 C-terminus and Threonine-735 phosphorylation.

Epithelial cell ADAM17 activation by Helicobacter pylori: role of ADAM17 C-terminus and Threonine-735 phosphorylation.

Journal: Microbes and infection
Published: June 02, 2014

Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.

Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.

Journal: Molecular immunology
Published: October 01, 2013

Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.

Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.

Journal: PloS one
Published: January 30, 2012

Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients.

Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients.

Journal: Blood
Published: December 14, 2011
Showing 1-11 of 11

Last Updated: 09/26/2026